Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience
{{output}}
Introduction: Tildrakizumab, a selective interleukin (IL)-23 p19 inhibitor, is an established treatment for moderate-to-severe plaque psoriasis. However, clinical trials are characterized by strict eligibility criteria, which oft... ...
